Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18218825 | 0.85 | HDAC6 (0.34) | MEN1KMT2A | |
| SCHEMBL18206072 | 0.83 | KDM4E (0.35) | POLBKDM4ETDP1ATMNPSR1 | |
| SCHEMBL18207163 | 0.83 | KDM4E (0.35) | POLBKDM4ETDP1ATMNPSR1 | |
| SCHEMBL18207164 | 0.83 | KDM4E (0.35) | POLBKDM4ETDP1ATMNPSR1 | |
| SCHEMBL30718117 | 0.83 | ACE (0.47) | POLBKDM4ETDP1ATMNPSR1 | |
| SCHEMBL31270971 | 0.76 | KLK5 (0.42) | POLBKDM4ETDP1ATMNPSR1 | |
| SCHEMBL31094599 | 0.76 | SCN9A (0.35) | CCKBR | |
| SCHEMBL6942067 | 0.74 | MAPT (0.43) | POLBTDP1ATMNPSR1MEN1 | |
| SCHEMBL5873703 | 0.74 | — | — | |
| SCHEMBL2853525 | 0.74 | MAPT (0.45) | POLBKDM4ETDP1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | POLB 1797/4885KDM4E 2266/4885TDP1 3101/4885 |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | POLB 1797/4885KDM4E 2266/4885TDP1 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.